An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
NCT05879614
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Revised development strategy
Conditions
Prader-Willi Syndrome
Interventions
DRUG:
NNZ-2591
Sponsor
Neuren Pharmaceuticals Limited